ARMP vs INNV vs ALHC vs PHGE

For growth investors, Alignment Healthcare, Inc.

(ALHC) is the stronger pick with 46. 1% revenue growth year-over-year, versus -5. 2% for Armata Pharmaceuticals, Inc. (ARMP). Analysts rate Armata Pharmaceuticals, Inc. (ARMP) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Armata Pharmaceuticals, Inc.

(ARMP) delivered a total return of +102. 4%, compared to -99. 9% for BiomX Inc. (PHGE). Over 10 years, the gap is even starker: ALHC returned +3. 6% versus PHGE's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alignment Healthcare, Inc.

(ALHC) is the lower-risk stock at 0. 81β versus InnovAge Holding Corp. 's 1. 49β — meaning INNV is approximately 84% more volatile than ALHC relative to the S&P 500. On balance sheet safety, InnovAge Holding Corp. (INNV) carries a lower debt/equity ratio of 38% versus 189% for Alignment Healthcare, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Alignment Healthcare, Inc.

(ALHC) is pulling ahead at 46. 1% versus -5. 2% for Armata Pharmaceuticals, Inc. (ARMP). On earnings-per-share growth, the picture is similar: Alignment Healthcare, Inc. grew EPS 99. 4% year-over-year, compared to -817. 6% for Armata Pharmaceuticals, Inc.. Over a 3-year CAGR, ALHC leads at 40. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

BiomX Inc.

(PHGE) is the more profitable company, earning 0. 0% net margin versus -35. 4% for Armata Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALHC leads at 0. 4% versus -636. 7% for ARMP. At the gross margin level — before operating expenses — ARMP leads at 68. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, InnovAge Holding Corp.

(INNV) trades at 36. 8x forward P/E versus 101. 8x for Alignment Healthcare, Inc. — 65. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PHGE: 5960. 6% to $38. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Alignment Healthcare, Inc.

(ALHC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 81)). Both have compounded well over 10 years (ALHC: +3. 6%, INNV: -68. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the null sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ARMP is a small-cap quality compounder stock; INNV is a small-cap quality compounder stock; ALHC is a small-cap high-growth stock; PHGE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.